Entropy Neurodynamics to Release Escrowed Shares and Options, Boosting Liquidity

The latest announcement is out from Tryptamine Therapeutics ( (AU:ENP) ).

Entropy Neurodynamics Limited, a clinical-stage biotechnology company developing psilocin-based psychedelic therapies, is advancing its lead IV psilocin program TRP-8803 to address limitations of oral psilocybin and leverage positive Phase 2a data in several hard-to-treat conditions. The company targets diseases with unmet medical need and aims to deliver more controllable, commercially practical psychedelic-assisted treatments.

The company has disclosed that 49,873,318 fully paid ordinary shares and a large suite of unlisted options will be released from escrow on 29 May 2026, after which no securities will remain in escrow. Entropy Neurodynamics will seek quotation for the newly released ordinary shares within five business days of the escrow expiry, while any underlying shares issued on future option exercises will be quoted at that time, increasing potential share liquidity and flexibility for existing holders and prospective investors.

More about Tryptamine Therapeutics

Entropy Neurodynamics Limited is a clinical-stage biotechnology company focused on developing proprietary formulations of psilocin administered with psychotherapy to treat diseases with unmet medical needs. Its lead program, TRP-8803, is an intravenous psilocin formulation designed to improve on oral psilocybin by speeding onset, controlling the depth and duration of the psychedelic experience, and shortening treatment sessions to commercially feasible timeframes. Previous Phase 2a trials using oral psilocybin in binge eating disorder, irritable bowel syndrome and fibromyalgia have demonstrated clinical benefits that inform the ongoing development of TRP-8803.

Average Trading Volume: 2,299,767

Technical Sentiment Signal: Buy

Current Market Cap: A$62.01M

For an in-depth examination of ENP stock, go to TipRanks’ Overview page.